succinobucol has been researched along with probucol in 52 studies
| Studies (succinobucol) | Trials (succinobucol) | Recent Studies (post-2010) (succinobucol) | Studies (probucol) | Trials (probucol) | Recent Studies (post-2010) (probucol) |
|---|---|---|---|---|---|
| 53 | 5 | 16 | 1,488 | 174 | 317 |
| Protein | Taxonomy | succinobucol (IC50) | probucol (IC50) |
|---|---|---|---|
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | Homo sapiens (human) | 1.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 33 (63.46) | 29.6817 |
| 2010's | 19 (36.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hill, RR; Holt, LA; Hoong, LK; Kunsch, C; Meng, CQ; Olliff, LK; Parthasarathy, S; Rachita, CL; Saxena, U; Sikorski, JA; Simpson, JE; Somers, PK; Sundell, CL; Wasserman, MA; Zheng, XS | 1 |
| Hill, RR; Hoong, LK; Hotema, MR; Howard, RB; Kunsch, C; Landers, LK; Luchoomun, J; MacDOnald, ML; Marino, EM; Meng, CQ; Saxena, U; Sikorski, JA; Simpson, JE; Somers, PK; Stefanopoulos, D; Suen, KL; Sundell, CL; Wasserman, MA; Weingarten, MD; Worsencroft, KJ; Ye, Z; Zheng, XS | 1 |
| Senior, K | 1 |
| Bourassa, MG; Glass, M; Grégoire, J; Guertin, MC; L'Allier, PL; Lambert, J; Laramée, L; Lespérance, J; Reeves, F; Schwartz, L; Tardif, JC; Title, L | 1 |
| Alexander, RW; Butteiger, D; Chapman, A; Daugherty, A; Edwards, D; Hill, RR; Hoong, LK; Jones, M; Landers, LK; Medford, RM; Meng, CQ; Saxena, U; Somers, PK; Suen, KL; Sundell, CL; Wasserman, MA | 1 |
| Edwards, D; Kunsch, C; Medford, RM; Meng, CQ; Sundell, CL; Wasserman, MA | 1 |
| Tardif, JC | 3 |
| Stix, G | 1 |
| Doggrell, SA | 1 |
| Arrendale, RF; Grey, JY; Kunsch, C; Luchoomun, J; Medford, RM; Olliff, LK; Saint, LB; Saxena, U; Wasserman, MA | 1 |
| Grégoire, J; L'Allier, PL; Lavoie, MA; Tardif, JC | 2 |
| Franks, AM; Gardner, SF | 1 |
| Cynshi, O; Stocker, R | 1 |
| Ransom, J | 1 |
| Malinin, A; Scott, R; Serebruany, V | 1 |
| Veryard, C | 1 |
| Anderson, TJ; Bertrand, OF; Brennan, ML; Grégoire, J; Guertin, MC; Hazen, SL; Ibrahim, R; L'Allier, PL; LeMay, M; Lespérance, J; Reeves, F; Schampaert, E; Scott, R; Tardif, JC; Title, LM | 1 |
| Preiss, DJ; Sattar, N | 1 |
| Benson, AP; Christensen, VL; Davis, AJ; Fairchild, BD; Hoffman, JB | 1 |
| Tanimoto, T | 1 |
| Eisert, C; Malinin, A; Ong, S; Serebruany, VL | 1 |
| Douglas, JS | 1 |
| Horowitz, J; Kaski, JC; McMurray, JJ; Recio-Mayoral, A; Remme, WJ; van Veldhuisen, DJ | 1 |
| Dart, AM; Duffy, SJ | 1 |
| Choi, J; Cooper, J; Klug, E; L'Allier, PL; Lewis, EF; McMurray, JJ; Pfeffer, MA; Schumi, J; Scott, R; Small, R; Tardif, JC | 1 |
| Kunsch, C; Malinin, A; Qiu, FH; Scott, R; Serebruany, V; Xu, XC | 1 |
| Li, G; Liu, T | 1 |
| Franks, AM; Muldrew, KM | 1 |
| Stocker, R | 1 |
| Beck, K; Cassano, C; Changsiri, D; Gamble, JR; Midwinter, RG; Stocker, R; Wang, Y; Wu, BJ | 1 |
| Lovering, RM; Michaelson, L; Ward, CW | 1 |
| Carter, JD; Cole, BK; Crim, WS; Kunsch, C; Mirmira, RG; Nadler, JL; Nunemaker, CS; Trace, AP; Wu, R | 1 |
| Inazu, A | 1 |
| Buřičová, L; Drašar, P; Galandáková, A; Horníček, J; Ikonen, S; Jurček, O; Kolehmainen, ET; Ulrichová, J; Wimmer, Z; Wimmerová, M | 1 |
| Belikova, NA; Cai, H; Dennis, JM; Dong, LF; Kagan, VE; Kapralov, AA; Khachigian, L; Maghzal, GJ; Midwinter, RG; Neuzil, J; Stocker, R; Tyurina, YY; Wu, BJ | 1 |
| Drašar, P; Jurček, O; Kolehmainen, E; Lahtinen, M; Wimmer, Z | 1 |
| Agbani, EO; Behnisch, B; Czudaj, P; Kennedy, S; McCormick, C; McPhaden, A; Mullen, A; Oldroyd, KG; Wadsworth, RM; Watt, J | 1 |
| Gómez, G; Lagakos, SW | 1 |
| Biswal, S | 1 |
| Braga, AL; Colle, D; Farina, M; Godoi, M; Hartwig, JM; Santos, DB | 1 |
| Kourounakis, AP; Ladopoulou, E; Matralis, AN | 1 |
| Belik, J; Kasirer, MY; Pan, J; Shifrin, Y; Welsh, C | 1 |
| Cao, H; Chen, L; Gu, W; He, X; Li, Y; Yin, Q; Yu, H; Zhang, Z; Zhao, S | 1 |
| Braga, AL; Colle, D; de Bem, AF; Engel, DF; Farina, M; Godoi, M; Hartwig, JM; Santos, DB | 1 |
| Bao, X; Cao, H; He, X; Li, Y; Yin, Q; Yu, H; Zhang, Z | 1 |
| Cao, H; Dan, Z; He, X; Li, Y; Shen, Q; Xu, M; Xu, Y; Yin, Q; Yu, H; Zeng, L; Zhang, P; Zhang, Z; Zhong, D; Zou, L | 1 |
| Braga, AL; Colle, D; Dias, PF; Farina, M; Ghizoni, H; Godoi, M; Gonçalves, CL; Hort, MA; Naime, AA; Ribeiro, RP; Santos, DB | 1 |
| Gnanadesikan, S; Houston, SA; Kennedy, S; Ugusman, A | 1 |
| Chen, Y; Liu, Z; Shi, S; Wang, X; Zhang, Y; Zheng, Z; Zhu, H | 1 |
16 review(s) available for succinobucol and probucol
| Article | Year |
|---|---|
Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease.
Topics: Antioxidants; Arteriosclerosis; Cardiovascular System; Coronary Artery Disease; Humans; Probucol; Signal Transduction | 2003 |
Clinical results with AGI-1067: a novel antioxidant vascular protectant.
Topics: Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Humans; Oxidative Stress; Probucol | 2003 |
Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronary Restenosis; Disease Models, Animal; Endothelium, Vascular; Humans; Probucol | 2003 |
Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Clinical Trials as Topic; Coronary Artery Disease; Coronary Restenosis; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; ortho-Aminobenzoates; Oxidative Stress; Probucol; Sirolimus; Vitamins | 2003 |
Vascular protectants for the treatment of atherosclerosis.
Topics: Antioxidants; Coronary Artery Disease; Humans; Probucol; Protective Agents; Randomized Controlled Trials as Topic; Research Design | 2003 |
Antioxidants and atherosclerosis: emerging drug therapies.
Topics: Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronary Restenosis; Humans; Oxidative Stress; Probucol | 2005 |
AGI-1067: a novel vascular protectant for prevention of restenosis.
Topics: Animals; Antioxidants; Clinical Trials as Topic; Coronary Restenosis; Drugs, Investigational; Humans; Molecular Structure; Probucol | 2006 |
Antioxidants: the good, the bad and the ugly.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Atherosclerosis; Coronary Restenosis; Humans; Oxidative Stress; Probucol; Vitamins | 2006 |
Inhibition of lipoprotein lipid oxidation.
Topics: Animals; Antioxidants; Atherosclerosis; Benzofurans; Cardiovascular Diseases; Humans; Lipoproteins, LDL; Malondialdehyde; Oxidation-Reduction; Probucol; Thiobarbituric Acid Reactive Substances | 2005 |
Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?
Topics: Antioxidants; Atherosclerosis; Endothelium, Vascular; Evidence-Based Medicine; Gene Expression Regulation; Humans; Probucol; Vascular Cell Adhesion Molecule-1 | 2007 |
[Research and developmental strategy of anti-dyslipidemic agents].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Apolipoprotein A-I; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Disease; Disease Models, Animal; Drug Design; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Oligoribonucleotides, Antisense; Probucol; Receptors, G-Protein-Coupled; Receptors, Nicotinic | 2007 |
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Platelets; Coronary Artery Disease; Coronary Restenosis; Cytokines; Disease Progression; Humans; Hypolipidemic Agents; Oxidative Stress; Platelet Aggregation Inhibitors; Probucol; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2007 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Humans; ortho-Aminobenzoates; Pioglitazone; Platelet Aggregation Inhibitors; Probucol; Risk Factors; Stents; Tetrazoles; Thiazolidinediones; Trapidil; Treatment Outcome | 2007 |
Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects.
Topics: Animals; Cardiovascular System; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Tolerance; Humans; Platelet Aggregation Inhibitors; Probucol | 2009 |
Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues.
Topics: Animals; Atherosclerosis; Diabetes Mellitus; Humans; Hypoglycemic Agents; Probucol | 2009 |
[Novel therapy for atherosclerosis and inflammatory vascular disease].
Topics: Acetates; Amides; Apolipoprotein A-I; Atherosclerosis; Benzaldehydes; Blood Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Design; Esters; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oxazolidinones; Oximes; Probucol; Quinazolines; Quinazolinones; Sulfhydryl Compounds | 2011 |
5 trial(s) available for succinobucol and probucol
| Article | Year |
|---|---|
Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Coronary Disease; Coronary Restenosis; Coronary Vessels; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Probucol; Stents; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency | 2003 |
Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.
Topics: Aged; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peroxidase; Probucol; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Novel cardiac therapies and innocent by standers.
Topics: Antioxidants; Coronary Disease; Double-Blind Method; Humans; Probucol | 2008 |
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Middle Aged; Probucol | 2008 |
Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
Topics: Adolescent; Adult; Aged; Biomarkers; Cells, Cultured; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Lipoproteins; Male; Middle Aged; Probucol; Risk Factors; Thromboxanes; Vascular Diseases; Young Adult | 2009 |
31 other study(ies) available for succinobucol and probucol
| Article | Year |
|---|---|
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
Topics: Animals; Antioxidants; Arteriosclerosis; Humans; Phenols; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2002 |
Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antioxidants; Cells, Cultured; Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Cricetinae; Depression, Chemical; Endothelial Cells; Endothelium, Vascular; Humans; Inflammation; Interleukin-1; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Phenols; Probucol; Structure-Activity Relationship; Sulfides; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2004 |
Drug reverses coronary atherosclerosis.
Topics: Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Coronary Vessels; Humans; Probucol | 2002 |
AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Disease Models, Animal; Endothelium, Vascular; Humans; Lipid Metabolism; Macaca fascicularis; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Probucol | 2003 |
Signal jammer. An academic experiment leads to a new class of drug for attacking heart disease.
Topics: Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Drug Industry; Heart Diseases; Humans; Probucol | 2003 |
Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent.
Topics: Active Transport, Cell Nucleus; Anti-Inflammatory Agents; Antioxidants; Aorta; Cells, Cultured; Cytokines; Drug Interactions; Endothelium, Vascular; Gene Expression; Humans; Leukocytes, Mononuclear; Monocytes; NF-kappa B; Oxidation-Reduction; Probucol; Transcriptional Activation; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2004 |
Are small biotechs still underselling themselves?
Topics: Biotechnology; Capital Financing; Drug Industry; Heart; Humans; Inflammation; Investments; Marketing; Myocardium; Probucol; Research Support as Topic; Technology, Pharmaceutical | 2006 |
The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease.
Topics: Adult; Antigens, CD; Antioxidants; Baltimore; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Female; Flow Cytometry; Humans; Linear Models; Male; Middle Aged; Platelet Aggregation; Platelet Membrane Glycoproteins; Probucol; Receptors, Cell Surface; Risk Factors; Vascular Diseases | 2006 |
American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders.
Topics: Animals; Cell- and Tissue-Based Therapy; Cholesterol, LDL; Coronary Disease; Endothelial Cells; Erythropoietin; Extremities; Fibroblast Growth Factor 2; Humans; Ischemia; Lipid Metabolism Disorders; Myocardial Infarction; Niacin; Probucol | 2007 |
Follicular development and expression of the messenger ribonucleic acid for the inhibin/activin subunits in two genetic lines of turkey hens that differ in total egg production.
Topics: Activins; Animals; Female; Follistatin; Gene Expression Regulation; Inhibins; Ovarian Follicle; Oviposition; Probucol; Protein Subunits; RNA, Messenger; Turkeys | 2007 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Europe; Fumarates; Heart Diseases; Heart Failure; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptide Fragments; Probucol; Recombinant Proteins; Ticlopidine; Tolvaptan | 2007 |
Probucol and succinobucol in atrial fibrillation: pros and cons.
Topics: Anticholesteremic Agents; Atrial Fibrillation; Humans; Probucol | 2010 |
Heme oxygenase-1 increases endothelial progenitor cells.
Topics: Animals; Antigens, Ly; Carbon Monoxide; Cells, Cultured; Endothelial Cells; Enzyme Induction; Hematopoietic Stem Cells; Heme Oxygenase-1; Hyperplasia; Membrane Proteins; Mice; Probucol; Rabbits; Tunica Intima; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Malformed mdx myofibers have normal cytoskeletal architecture yet altered EC coupling and stress-induced Ca2+ signaling.
Topics: Animals; Calcium; Calcium Signaling; Dystrophin; Mice; Mice, Inbred mdx; Muscle Contraction; Muscle Fibers, Skeletal; Osmotic Pressure; Probucol; Protein Transport | 2009 |
AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets.
Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Antioxidants; Calcium; Cell Death; Cytokines; Diazoxide; Gene Expression; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Keto Acids; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; Potassium Channels; Probucol; Tolbutamide | 2010 |
Succinobucol's new coat--conjugation with steroids to alter its drug effect and bioavailability.
Topics: 3T3 Cells; Animals; Anti-Inflammatory Agents; Antioxidants; Biological Availability; Biphenyl Compounds; Clinical Trials as Topic; Fibroblasts; Free Radicals; Humans; Mice; Mice, Inbred BALB C; Molecular Structure; Picrates; Probucol; Static Electricity; Steroids | 2011 |
Succinobucol induces apoptosis in vascular smooth muscle cells.
Topics: Animals; Aorta; Apoptosis; Caspase 3; Cell Proliferation; Cell Survival; Cells, Cultured; Cytochromes c; DNA Fragmentation; Electron Transport Complex II; Enzyme Induction; Heme Oxygenase-1; Hydrogen Peroxide; Male; Metalloporphyrins; Mitochondria; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Probucol; Protoporphyrins; Rabbits; Rats | 2012 |
Crystallization, spectral, crystallographical, and thermoanalytical studies of succinobucol polymorphism.
Topics: Calorimetry, Differential Scanning; Crystallization; Crystallography, X-Ray; Magnetic Resonance Spectroscopy; Models, Molecular; Powder Diffraction; Probucol; Spectrophotometry, Infrared; Thermogravimetry | 2012 |
Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model.
Topics: Animals; Cardiovascular Agents; Cattle; Cell Survival; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Endothelial Cells; Fibrin; Inflammation; Male; Metals; Models, Animal; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Percutaneous Coronary Intervention; Probucol; Prosthesis Design; Sirolimus; Swine | 2013 |
Statistical considerations when using a composite endpoint for comparing treatment groups.
Topics: Acute Coronary Syndrome; AIDS Vaccines; Anti-HIV Agents; Anticholesteremic Agents; Biostatistics; Endpoint Determination; HIV Infections; Humans; Probucol; Randomized Controlled Trials as Topic | 2013 |
Novel cardiovascular drugs in clinical trials.
Topics: Anticholesteremic Agents; Benzaldehydes; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrinolytic Agents; Humans; Immunologic Factors; Isoxazoles; Lipoxygenase Inhibitors; Metalloendopeptidases; Oxazolidinones; Oximes; Phospholipase A2 Inhibitors; Probucol; Pyrimidines; Quinolines; Thiophenes | 2010 |
Succinobucol versus probucol: higher efficiency of succinobucol in mitigating 3-NP-induced brain mitochondrial dysfunction and oxidative stress in vitro.
Topics: Animals; Antioxidants; Brain; Electron Transport Complex II; Male; Mitochondria; Nitro Compounds; Oxidative Stress; Probucol; Propionates; Rats; Rats, Wistar | 2013 |
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats | 2013 |
Metoclopramide does not increase gastric muscle contractility in newborn rats.
Topics: Animals; Animals, Newborn; Dopamine Antagonists; Electrophysiological Phenomena; Gastrointestinal Transit; Metoclopramide; Muscle Contraction; Muscle, Smooth; Probucol; Random Allocation; Rats; Rats, Sprague-Dawley; Stomach | 2014 |
Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Breast Neoplasms; Cell Movement; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Female; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasm Invasiveness; Particle Size; Poloxamer; Probucol; Rats, Sprague-Dawley; RAW 264.7 Cells; Signal Transduction; Technology, Pharmaceutical; Tissue Distribution; Vascular Cell Adhesion Molecule-1 | 2015 |
Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity.
Topics: Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; Cell Survival; Glutamate-Cysteine Ligase; Glutathione; Glutathione Peroxidase; Humans; Hydroquinones; Hypolipidemic Agents; Mitochondria; Nitro Compounds; Oxidative Stress; Probucol; Propionates; Protective Agents; RNA, Messenger; Time Factors; Up-Regulation | 2016 |
pH-Responsive Wormlike Micelles with Sequential Metastasis Targeting Inhibit Lung Metastasis of Breast Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Female; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Neoplasm Metastasis; Polyethylene Glycols; Probucol; RAW 264.7 Cells; Vascular Cell Adhesion Molecule-1 | 2016 |
A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer.
Topics: Animals; Antineoplastic Agents; beta-Cyclodextrins; Breast Neoplasms; Cell Movement; Disease Models, Animal; Drug Delivery Systems; Female; Hydrogen-Ion Concentration; Lung Neoplasms; Mice, Inbred BALB C; Nanostructures; Neoplasm Invasiveness; Polyethylene Glycols; Probucol; Treatment Outcome | 2016 |
Decreased forelimb ability in mice intracerebroventricularly injected with low dose 6-hydroxidopamine: A model on the dissociation of bradykinesia from hypokinesia.
Topics: Adrenergic Agents; Animals; Dose-Response Relationship, Drug; Exploratory Behavior; Feeding Behavior; Forelimb; Glutathione Peroxidase; Glutathione Reductase; Histocompatibility Antigens Class I; Hypokinesia; Injections, Intraventricular; Lipid Peroxidation; Male; Mice; Muscle Strength; Oxidopamine; Peptide Fragments; Probucol; Psychomotor Performance; Thiobarbituric Acid Reactive Substances | 2016 |
An investigation of the antiplatelet effects of succinobucol (AGI-1067).
Topics: Adenosine Diphosphate; Animals; Antioxidants; Blood Platelets; Blood Pressure; Collagen; Heart Rate; Iliac Artery; Male; Myography; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet-Rich Plasma; Probucol; Rabbits; Rats; Rats, Sprague-Dawley; Tissue Culture Techniques; Xanthine; Xanthine Oxidase | 2017 |
Novel ASK1 Inhibitor AGI-1067 Attenuates AGE-Induced Fibrotic Response by Suppressing the MKKs/p38 MAPK Pathway in Human Coronary Arterial Smooth Muscle Cells.
Topics: Blotting, Western; Cardiovascular Agents; Cells, Cultured; Coronary Vessels; Fibrosis; Glycation End Products, Advanced; Humans; Immunoprecipitation; MAP Kinase Kinase 3; MAP Kinase Kinase 6; MAP Kinase Kinase Kinase 5; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Probucol; Signal Transduction | 2018 |